当前位置：
X-MOL 学术
›
Cancer Med.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
High serum PD-L1 level is a poor prognostic biomarker in surgically treated esophageal cancer.
Cancer Medicine ( IF 2.9 ) Pub Date : 2019-12-21 , DOI: 10.1002/cam4.2789 Masaaki Ito 1 , Satoshi Yajima 2 , Takashi Suzuki 2 , Yoko Oshima 2 , Tatsuki Nanami 2 , Makoto Sumazaki 2 , Fumiaki Shiratori 2 , Kimihiko Funahashi 2 , Naobumi Tochigi 3 , Hideaki Shimada 1, 2
Cancer Medicine ( IF 2.9 ) Pub Date : 2019-12-21 , DOI: 10.1002/cam4.2789 Masaaki Ito 1 , Satoshi Yajima 2 , Takashi Suzuki 2 , Yoko Oshima 2 , Tatsuki Nanami 2 , Makoto Sumazaki 2 , Fumiaki Shiratori 2 , Kimihiko Funahashi 2 , Naobumi Tochigi 3 , Hideaki Shimada 1, 2
Affiliation
|
BACKGROUND
Programmed death ligand 1 (PD-L1) inhibitor has been approved as one of the standard therapies for various cancers. Some reports have shown that serum PD-L1 level is associated with advanced tumor stages and poor prognosis; however, corresponding pathological information in esophageal cancer patients is lacking. Therefore, we evaluated the clinicopathological and prognostic impact of serum PD-L1 levels in surgically treated esophageal cancer.
METHODS
A total of 150 patients who underwent radical resection for esophageal cancer were included in the study. Preoperative serum PD-L1 levels were analyzed using the enzyme-linked immunosorbent assay kit. A cutoff level of 65.6 pg/mL was used to divide the patients into two groups, and univariate and multivariate analyses were conducted to compare the clinicopathological characteristics and prognoses between these two groups.
RESULTS
Although significant associations between serum PD-L1 levels and clinicopathological variables were observed, serum PD-L1 level was significantly associated with high neutrophil counts, high CRP levels, low albumin levels, and high squamous cell carcinoma antigen levels. Furthermore, serum PD-L1 level was associated with poor overall survival independent to TNM factors.
CONCLUSIONS
High preoperative level of serum PD-L1 is a prognostic factor for poor overall survival in patients with surgically treated esophageal cancer.
中文翻译：
高血清 PD-L1 水平是手术治疗食管癌的不良预后生物标志物。
背景程序性死亡配体1（PD-L1）抑制剂已被批准作为多种癌症的标准疗法之一。有报道显示血清PD-L1水平与肿瘤分期晚期和不良预后相关；然而，食管癌患者缺乏相应的病理信息。因此，我们评估了手术治疗的食管癌血清PD-L1水平的临床病理学和预后影响。方法 共纳入 150 例接受食管癌根治术的患者。使用酶联免疫吸附测定试剂盒分析术前血清PD-L1水平。以65.6 pg/mL为临界水平将患者分为两组，并进行单因素和多因素分析比较两组的临床病理特征和预后。结果 尽管观察到血清 PD-L1 水平与临床病理变量之间存在显着相关性，但血清 PD-L1 水平与高中性粒细胞计数、高 CRP 水平、低白蛋白水平和高鳞状细胞癌抗原水平显着相关。此外，血清 PD-L1 水平与较差的总体生存率相关，与 TNM 因素无关。结论 术前血清 PD-L1 水平较高是食管癌手术治疗患者总生存期较差的一个预后因素。
更新日期：2019-12-22
中文翻译：
高血清 PD-L1 水平是手术治疗食管癌的不良预后生物标志物。
背景程序性死亡配体1（PD-L1）抑制剂已被批准作为多种癌症的标准疗法之一。有报道显示血清PD-L1水平与肿瘤分期晚期和不良预后相关；然而，食管癌患者缺乏相应的病理信息。因此，我们评估了手术治疗的食管癌血清PD-L1水平的临床病理学和预后影响。方法 共纳入 150 例接受食管癌根治术的患者。使用酶联免疫吸附测定试剂盒分析术前血清PD-L1水平。以65.6 pg/mL为临界水平将患者分为两组，并进行单因素和多因素分析比较两组的临床病理特征和预后。结果 尽管观察到血清 PD-L1 水平与临床病理变量之间存在显着相关性，但血清 PD-L1 水平与高中性粒细胞计数、高 CRP 水平、低白蛋白水平和高鳞状细胞癌抗原水平显着相关。此外，血清 PD-L1 水平与较差的总体生存率相关，与 TNM 因素无关。结论 术前血清 PD-L1 水平较高是食管癌手术治疗患者总生存期较差的一个预后因素。
京公网安备 11010802027423号